secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zeo ScientifiX, Inc. (ZEOX)
CIK:        0001557376
Form:       8-K
Filed at:   2024-09-20T23:59:59+00:00
Accession:  0001829126-24-006382
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Zeo ScientifiX completes Phase 1 trials for Zofin; seeks Phase 2 trials
-----------------------------------------------------------------------

- Completed Phase 1 clinical trials for flagship product Zofin; actively seeking to commence Phase 2 trials for multiple indications.
- Partnered with Exotropin to develop topical aesthetic and anti-aging products using exosome technology; holds minority stake.
- Changed name from Organicell Regenerative Medicine to Zeo ScientifiX in February 2024 to reflect scientific focus.
- Regenerative medicine market projected to grow to $175B by 2032 at 22.8% CAGR, per Precedence Research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557376/000182912624006382/0001829126-24-006382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557376/000182912624006382/zeoscientifix_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-24-006382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer